CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: RNF213 (ImmuneEditome ID:57674)

1. Gene summary of enriched editing regions for RNF213

check button Gene summary
Gene informationGene symbol

RNF213

Gene ID

57674

GeneSynonymsALO17|C17orf27|KIAA1618|MYMY2|MYSTR|NET57
GeneCytomap

17q25.3

GeneTypeprotein-coding
GeneDescriptionE3 ubiquitin-protein ligase RNF213|protein ALO17|ALK lymphoma oligomerization partner on chromosome 17|E3 ubiquitin-lipopolysaccharide ligase RNF213|RING-type E3 ubiquitin transferase RNF213|mysterin
GeneModificationdate20230528
UniprotIDA0A0A0MTC1;A0A0A0MTR7
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr17:80266309-80268052:+ENST00000319921.4ENSG00000173821.18RNF213intronicTigger1,AluSz,AluSx,AluSc,AluJbchr17:80266309-80268052:+.alignment
chr17:80266309-80268052:+ENST00000508628.5ENSG00000173821.18RNF213intronicTigger1,AluSz,AluSx,AluSc,AluJbchr17:80266309-80268052:+.alignment
chr17:80266309-80268052:+ENST00000582970.4ENSG00000173821.18RNF213intronicTigger1,AluSz,AluSx,AluSc,AluJbchr17:80266309-80268052:+.alignment
chr17:80276818-80277540:+ENST00000319921.4ENSG00000173821.18RNF213intronicL1MB7,AluSz,AluSc5chr17:80276818-80277540:+.alignment
chr17:80276818-80277540:+ENST00000508628.5ENSG00000173821.18RNF213intronicL1MB7,AluSz,AluSc5chr17:80276818-80277540:+.alignment
chr17:80276818-80277540:+ENST00000582970.4ENSG00000173821.18RNF213intronicL1MB7,AluSz,AluSc5chr17:80276818-80277540:+.alignment
chr17:80301475-80301739:+ENST00000559070.4ENSG00000173821.18RNF213ncRNA_intronicL1MA5chr17:80301475-80301739:+.alignment
chr17:80320359-80321024:+ENST00000559070.4ENSG00000173821.18RNF213ncRNA_intronicAluSp,L1MB7,AluJrchr17:80320359-80321024:+.alignment
chr17:80322173-80322566:+ENST00000559070.4ENSG00000173821.18RNF213ncRNA_intronicAluSc8,AluJbchr17:80322173-80322566:+.alignment


Top

2. Tumor-specific enriched editing regions for RNF213


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
ENSG00000173821.18,RNF213KIRCEAG4.8144e-02image
chr17:80320359-80321024:+KIRPEER6.8595e-03image
ENSG00000173821.18,RNF213KIRPEAG6.9020e-03image
chr17:80320359-80321024:+THCAEER2.4184e-03image
ENSG00000173821.18,RNF213THCAEAG2.6997e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000173821.18,RNF213KIRPCliEAG2.8928e-026.2246e-030.2010image
chr17:80320359-80321024:+KIRPCliEER3.0192e-027.2397e-030.1974image
ENSG00000173821.18,RNF213PAADPathEAG1.3469e-032.0477e-040.3990image
chr17:80320359-80321024:+PAADPathEER1.3469e-032.0477e-040.3990image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for RNF213


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr17:80320359-80321024:+OVEERENSG00000083845,RPS50.21711.3984e-027.1332e-120.4128imageNCNBP;EIF4A3;FMR1;FUS;LIN28B;RBM27;SRSF9;YTHDC1;YTHDF1;TAF15NAB_cells_memoryGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION

More results



Top

4. Enriched editing regions and immune related splicing for RNF213


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000173821.18,RNF213
ESCAEAGIRENSG00000131143.4chr1685804936:85805864:85806455:85806805-0.32943.7925e-021.2415e-06-0.4046imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAB_cells_naiveGSVA_HALLMARK_MTORC1_SIGNALING
ENSG00000173821.18,RNF213
ESCAEAGIRENSG00000132024.13chr1913919129:13919939:13920556:13920668-0.44241.0739e-031.2508e-07-0.4233imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;ZNF184NAT_cells_CD8GSVA_HALLMARK_GLYCOLYSIS
ENSG00000173821.18,RNF213
ESCAEAGIRENSG00000132024.13chr1913919129:13919951:13920559:13920668-0.37788.3939e-033.6568e-07-0.4169imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;ZNF184NADendritic_cells_restingGSVA_HALLMARK_GLYCOLYSIS
ENSG00000173821.18,RNF213
ESCAEAGIRENSG00000174720.11chr4112646790:112647127:112647198:112647449-0.38071.1790e-021.1170e-07-0.4248imageNACIN1;ADAR;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;RBM47;RBM6;RNF219;SAFB2;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_MTORC1_SIGNALING
ENSG00000173821.18,RNF213
ESCAEAGIRENSG00000075413.13chr14103467078:103467191:103468032:103468186-0.39665.1054e-032.8684e-07-0.4121imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184MARK3Macrophages_M0GSVA_HALLMARK_GLYCOLYSIS
chr17:80320359-80321024:+
ESCAEERIRENSG00000170296.5chr177241600:7241679:7242078:7242156-0.32642.5607e-025.5878e-06-0.4012imageNEIF4A3;FMR1;FUS;LIN28B;RBM27;SRSF9;YTHDC1;YTHDF1;TAF15NADendritic_cells_restingGSVA_HALLMARK_KRAS_SIGNALING_DN
ENSG00000173821.18,RNF213
ESCAEAGIRENSG00000073331.13chr4112427569:112429253:112430447:112432581-0.37639.4946e-037.7986e-07-0.4074imageNACIN1;ADAR;AIFM1;AUH;CELF2;CNBP;CSTF2T;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28B;LSM11;MOV10;MSI1;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM6;RNF219;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;TAF15;TARDBP;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAG;ZNF184NADendritic_cells_restingGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
ENSG00000173821.18,RNF213
ESCAEAGIRENSG00000174720.11chr4112646790:112646955:112647033:112647127-0.39367.7865e-032.4696e-07-0.4141imageNACIN1;ADAR;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;RBM47;RBM6;RNF219;SAFB2;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000173821.18,RNF213
STADEAGIRENSG00000186470.9chr626373275:26373413:26374326:26374373-0.41541.0163e-097.2443e-13-0.4011imageNADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;GNL3;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NOP56;NOP58;NPM1;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184BTN3A2B_cells_naiveGSVA_HALLMARK_HEME_METABOLISM
ENSG00000173821.18,RNF213
STADEAGIRENSG00000135596.13chr6109450299:109450557:109451599:109451700-0.40781.5982e-098.4214e-14-0.4210imageNADAR;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184NAMacrophages_M0GSVA_HALLMARK_HEME_METABOLISM

More results



Top

5. Enriched editing regions and immune infiltration for RNF213


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr17:80320359-80321024:+ACCEEREosinophils2.0358e-020.4083image
ENSG00000173821.18,RNF213ACCEAGEosinophils2.0358e-020.4083image
chr17:80320359-80321024:+BLCAEERT_cells_CD81.0039e-020.1629image
ENSG00000173821.18,RNF213BLCAEAGT_cells_CD87.4153e-030.1686image
ENSG00000173821.18,RNF213BRCAEAGT_cells_CD4_memory_resting8.0337e-03-0.0952image
chr17:80320359-80321024:+CESCEERNK_cells_resting4.4545e-02-0.1415image
chr17:80320359-80321024:+CHOLEERT_cells_CD4_memory_resting1.9878e-02-0.5159image
ENSG00000173821.18,RNF213CHOLEAGT_cells_CD4_memory_resting1.9878e-02-0.5159image
chr17:80320359-80321024:+COADEERMacrophages_M01.0386e-02-0.3045image
ENSG00000173821.18,RNF213COADEAGMast_cells_resting1.0307e-030.3692image
chr17:80266309-80268052:+ESCAEERMacrophages_M21.6975e-020.5032image
chr17:80320359-80321024:+ESCAEERDendritic_cells_resting2.6860e-030.2536image
ENSG00000173821.18,RNF213ESCAEAGDendritic_cells_resting6.1003e-040.2822image
chr17:80320359-80321024:+GBMEERPlasma_cells2.0602e-020.2373image
ENSG00000173821.18,RNF213GBMEAGPlasma_cells2.0602e-020.2373image
chr17:80320359-80321024:+HNSCEERNeutrophils4.4184e-020.1163image
ENSG00000173821.18,RNF213HNSCEAGNeutrophils4.4184e-020.1163image
chr17:80320359-80321024:+KIRCEERT_cells_CD4_naive6.0111e-030.1523image
ENSG00000173821.18,RNF213KIRCEAGT_cells_CD4_naive7.0206e-030.1493image
chr17:80320359-80321024:+KIRPEERT_cells_CD4_memory_resting7.2875e-03-0.1645image
ENSG00000173821.18,RNF213KIRPEAGT_cells_CD4_memory_resting7.4712e-03-0.1640image
ENSG00000173821.18,RNF213LAMLEAGT_cells_CD81.6540e-020.3816image
chr17:80320359-80321024:+LUADEERDendritic_cells_resting1.9657e-020.1284image
ENSG00000173821.18,RNF213LUADEAGEosinophils9.0569e-04-0.1813image
chr17:80320359-80321024:+LUSCEERMacrophages_M03.2766e-02-0.1153image
ENSG00000173821.18,RNF213LUSCEAGMacrophages_M03.2566e-02-0.1154image
chr17:80276818-80277540:+OVEERT_cells_CD4_naive2.5928e-020.4062image
chr17:80320359-80321024:+OVEERDendritic_cells_resting2.5106e-020.1405image
ENSG00000173821.18,RNF213OVEAGDendritic_cells_resting2.1555e-020.1433image
chr17:80320359-80321024:+PCPGEERNK_cells_resting4.9248e-020.2343image
ENSG00000173821.18,RNF213PCPGEAGNK_cells_resting4.9248e-020.2343image
chr17:80320359-80321024:+PRADEERDendritic_cells_resting3.6604e-03-0.2799image
ENSG00000173821.18,RNF213PRADEAGDendritic_cells_resting5.1944e-03-0.2684image
chr17:80320359-80321024:+SARCEERNeutrophils1.0379e-020.1961image
ENSG00000173821.18,RNF213SARCEAGNeutrophils1.0379e-020.1961image
chr17:80320359-80321024:+SKCMEERT_cells_gamma_delta2.0750e-02-0.1232image
ENSG00000173821.18,RNF213SKCMEAGT_cells_gamma_delta2.2300e-02-0.1216image
chr17:80320359-80321024:+STADEERNeutrophils6.6665e-030.1715image
ENSG00000173821.18,RNF213STADEAGB_cells_memory4.2315e-04-0.2036image
chr17:80320359-80321024:+TGCTEERMacrophages_M15.1867e-030.3932image
ENSG00000173821.18,RNF213TGCTEAGMacrophages_M15.1867e-030.3932image
chr17:80320359-80321024:+THCAEERB_cells_memory3.9060e-02-0.1186image
ENSG00000173821.18,RNF213THCAEAGB_cells_memory4.2614e-02-0.1166image
chr17:80320359-80321024:+THYMEERT_cells_gamma_delta4.1957e-020.2324image
ENSG00000173821.18,RNF213THYMEAGT_cells_gamma_delta4.1957e-020.2324image
chr17:80320359-80321024:+UCSEERMast_cells_activated4.0848e-020.3061image
ENSG00000173821.18,RNF213UCSEAGMast_cells_activated4.0848e-020.3061image
chr17:80320359-80321024:+UVMEERT_cells_CD4_naive2.1031e-020.4781image
ENSG00000173821.18,RNF213UVMEAGT_cells_CD4_naive2.1031e-020.4781image


Top

6. Enriched editing regions and immune gene sets for RNF213


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000173821.18,RNF213STADEAG1.1413e-020.14691.6971e-030.18171.4406e-020.14216.5172e-040.1970image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000173821.18,RNF213ACCGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG3.9018e-02-0.3666image
chr17:80320359-80321024:+ACCGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER3.9018e-02-0.3666image
ENSG00000173821.18,RNF213BLCAGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG1.0079e-030.2064image
chr17:80320359-80321024:+BLCAGSVA_HALLMARK_PROTEIN_SECRETIONEER1.5796e-030.1992image
chr17:80320359-80321024:+BRCAGSVA_HALLMARK_PROTEIN_SECRETIONEER1.5034e-040.1362image
ENSG00000173821.18,RNF213BRCAGSVA_HALLMARK_HEME_METABOLISMEAG9.0572e-060.1588image
chr17:80320359-80321024:+CESCGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER3.0896e-020.1519image
ENSG00000173821.18,RNF213CESCGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG3.3319e-020.1494image
ENSG00000173821.18,RNF213COADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.7505e-040.4175image
chr17:80320359-80321024:+ESCAGSVA_HALLMARK_HEME_METABOLISMEER1.3531e-040.3192image
ENSG00000173821.18,RNF213ESCAGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG2.9371e-050.3407image
ENSG00000173821.18,RNF213GBMGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.1866e-020.2572image
chr17:80320359-80321024:+GBMGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.1866e-020.2572image
chr17:80320359-80321024:+HNSCGSVA_HALLMARK_GLYCOLYSISEER3.4861e-030.1682image
ENSG00000173821.18,RNF213HNSCGSVA_HALLMARK_GLYCOLYSISEAG3.4861e-030.1682image
ENSG00000173821.18,RNF213KIRCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG4.1924e-030.1584image
chr17:80320359-80321024:+KIRCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER3.1367e-030.1636image
ENSG00000173821.18,RNF213KIRPGSVA_HALLMARK_KRAS_SIGNALING_DNEAG6.9190e-030.1655image
chr17:80320359-80321024:+KIRPGSVA_HALLMARK_KRAS_SIGNALING_DNEER6.8548e-030.1657image
ENSG00000173821.18,RNF213LAMLGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.0550e-03-0.4499image
ENSG00000173821.18,RNF213LGGGSVA_HALLMARK_PROTEIN_SECRETIONEAG5.6880e-030.1727image
chr17:80320359-80321024:+LGGGSVA_HALLMARK_PROTEIN_SECRETIONEER5.6880e-030.1727image
chr17:80320359-80321024:+LUADGSVA_HALLMARK_HEME_METABOLISMEER5.7446e-050.2196image
ENSG00000173821.18,RNF213LUADGSVA_HALLMARK_HEME_METABOLISMEAG1.0957e-070.2864image
chr17:80320359-80321024:+LUSCGSVA_HALLMARK_DNA_REPAIREER2.0284e-020.1253image
ENSG00000173821.18,RNF213LUSCGSVA_HALLMARK_DNA_REPAIREAG2.0053e-020.1255image
ENSG00000173821.18,RNF213OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.7846e-060.2928image
chr17:80320359-80321024:+OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER2.0409e-060.2929image
ENSG00000173821.18,RNF213PAADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG2.4144e-020.2489image
chr17:80320359-80321024:+PAADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER2.4144e-020.2489image
ENSG00000173821.18,RNF213PRADGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG1.1073e-020.2447image
chr17:80320359-80321024:+PRADGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER1.6460e-020.2325image
chr17:80266309-80268052:+STADGSVA_HALLMARK_PROTEIN_SECRETIONEER2.0740e-030.4065image
ENSG00000173821.18,RNF213STADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG2.5937e-080.3166image
chr17:80320359-80321024:+STADGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER5.2362e-040.2182image
ENSG00000173821.18,RNF213TGCTGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG3.3635e-030.4108image
chr17:80320359-80321024:+TGCTGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER3.3635e-030.4108image
chr17:80320359-80321024:+THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER1.0327e-040.2212image
ENSG00000173821.18,RNF213THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG8.8475e-050.2233image
chr17:80320359-80321024:+UCSGSVA_HALLMARK_MYOGENESISEER6.5765e-03-0.3993image
ENSG00000173821.18,RNF213UCSGSVA_HALLMARK_MYOGENESISEAG6.5765e-03-0.3993image
ENSG00000173821.18,RNF213UVMGSVA_HALLMARK_HEME_METABOLISMEAG1.7024e-020.4923image
chr17:80320359-80321024:+UVMGSVA_HALLMARK_HEME_METABOLISMEER1.7024e-020.4923image


Top

7. Enriched editing regions and drugs for RNF213


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000173821.18,RNF213ACCEmbelinEAG1.2481e-02-0.4366image
chr17:80320359-80321024:+ACCEmbelinEER1.2481e-02-0.4366image
ENSG00000173821.18,RNF213BLCAAxitinibEAG3.0256e-020.1368image
ENSG00000173821.18,RNF213BRCAABT.263EAG4.1079e-090.2095image
chr17:80320359-80321024:+BRCAABT.263EER9.4092e-080.1910image
chr17:80320359-80321024:+CESCBleomycinEER4.6479e-020.1403image
ENSG00000173821.18,RNF213CHOLBMS.536924EAG3.4600e-030.6212image
chr17:80320359-80321024:+CHOLBMS.536924EER3.4600e-030.6212image
chr17:80320359-80321024:+COADAG.014699EER3.5503e-02-0.2518image
ENSG00000173821.18,RNF213COADBMS.509744EAG5.1764e-06-0.4961image
chr17:80320359-80321024:+DLBCBI.2536EER4.8173e-030.5453image
ENSG00000173821.18,RNF213DLBCBI.2536EAG4.7982e-030.5455image
ENSG00000173821.18,RNF213ESCAKIN001.135EAG3.0588e-05-0.3400image
chr17:80320359-80321024:+ESCAGemcitabineEER1.1178e-040.3230image
ENSG00000173821.18,RNF213GBMBIRB.0796EAG2.7976e-020.2255image
chr17:80320359-80321024:+GBMBIRB.0796EER2.7976e-020.2255image
ENSG00000173821.18,RNF213KIRCBosutinibEAG6.9829e-030.1496image
chr17:80320359-80321024:+KIRCAZD.0530EER3.5912e-03-0.1613image
chr17:80320359-80321024:+KIRPDMOGEER4.4268e-03-0.1743image
ENSG00000173821.18,RNF213KIRPDMOGEAG4.2160e-03-0.1753image
ENSG00000173821.18,RNF213LAMLCCT018159EAG2.0593e-03-0.4785image
ENSG00000173821.18,RNF213LGGBMS.536924EAG1.8800e-020.1470image
chr17:80320359-80321024:+LGGBMS.536924EER1.8800e-020.1470image
chr17:80320359-80321024:+LIHCGSK.650394EER1.5230e-020.2610image
ENSG00000173821.18,RNF213LIHCGSK.650394EAG1.5230e-020.2610image
ENSG00000173821.18,RNF213LUADBexaroteneEAG7.2299e-07-0.2680image
chr17:80320359-80321024:+LUADABT.888EER1.5615e-040.2067image
ENSG00000173821.18,RNF213MESOBAY.61.3606EAG1.9417e-02-0.2808image
chr17:80320359-80321024:+MESOBAY.61.3606EER1.9417e-02-0.2808image
chr17:80276818-80277540:+OVGDC.0449EER2.8247e-03-0.5261image
chr17:80320359-80321024:+OVBMS.509744EER1.1310e-05-0.2716image
ENSG00000173821.18,RNF213OVBMS.509744EAG1.6586e-05-0.2651image
ENSG00000173821.18,RNF213PAADCHIR.99021EAG5.6581e-03-0.3048image
chr17:80320359-80321024:+PAADCHIR.99021EER5.6581e-03-0.3048image
ENSG00000173821.18,RNF213PCPGBosutinibEAG3.9048e-02-0.2455image
chr17:80320359-80321024:+PCPGBosutinibEER3.9048e-02-0.2455image
ENSG00000173821.18,RNF213PRADGDC0941EAG4.5640e-04-0.3330image
chr17:80320359-80321024:+PRADGDC0941EER6.6242e-04-0.3255image
chr17:80320359-80321024:+SARCDMOGEER2.3620e-03-0.2317image
ENSG00000173821.18,RNF213SARCDMOGEAG2.3620e-03-0.2317image
ENSG00000173821.18,RNF213SKCMAG.014699EAG5.6332e-030.1473image
chr17:80320359-80321024:+SKCMAG.014699EER4.8634e-030.1500image
ENSG00000173821.18,RNF213STADAG.014699EAG2.5491e-040.2111image
chr17:80266309-80268052:+STADCMKEER2.8702e-020.2951image
chr17:80320359-80321024:+STADAP.24534EER1.0777e-050.2749image
chr17:80320359-80321024:+TGCTA.443654EER2.0510e-020.3302image
ENSG00000173821.18,RNF213TGCTA.443654EAG2.0510e-020.3302image
ENSG00000173821.18,RNF213THCAAMG.706EAG4.6194e-050.2318image
chr17:80320359-80321024:+THCAAMG.706EER7.2282e-050.2260image
ENSG00000173821.18,RNF213UCECGDC.0449EAG1.2623e-03-0.3150image
chr17:80320359-80321024:+UCECGDC.0449EER2.0003e-02-0.2347image
ENSG00000173821.18,RNF213UCSEHT.1864EAG3.4216e-030.4272image
chr17:80320359-80321024:+UCSEHT.1864EER3.4216e-030.4272image
ENSG00000173821.18,RNF213UVMGemcitabineEAG3.3840e-030.5848image
chr17:80320359-80321024:+UVMGemcitabineEER3.3840e-030.5848image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType